<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>HIV Antiretroviral Drugs - Study Guide</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 100%;
            margin: 0 auto;
            background: white;
            border-radius: 15px;
            padding: 30px;
            box-shadow: 0 20px 40px rgba(0,0,0,0.1);
        }

        h1 {
            text-align: center;
            color: #333;
            margin-bottom: 10px;
            font-size: 2.5em;
        }

        .subtitle {
            text-align: center;
            color: #666;
            margin-bottom: 30px;
            font-size: 1.1em;
        }

        /* MAIN TABS */
        .main-tabs {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-bottom: 30px;
            border-bottom: 3px solid #667eea;
            padding-bottom: 10px;
        }

        .main-tab {
            padding: 12px 24px;
            background: #f5f5f5;
            border: none;
            border-radius: 10px 10px 0 0;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s;
            color: #666;
        }

        .main-tab:hover {
            background: #e8e8e8;
            transform: translateY(-2px);
        }

        .main-tab.active {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            transform: translateY(-2px);
        }

        /* SUB TABS */
        .tabs {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            margin-bottom: 25px;
            padding: 10px;
            background: #f8f9fa;
            border-radius: 10px;
        }

        .tab {
            padding: 10px 20px;
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.3s;
            font-weight: 500;
            color: #555;
        }

        .tab:hover {
            border-color: #667eea;
            background: #f0f4ff;
        }

        .tab.active {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-color: #667eea;
            transform: translateY(-2px);
        }

        /* SECTIONS */
        .main-section {
            display: none;
        }

        .main-section.active {
            display: block;
            animation: fadeIn 0.5s;
        }

        .content-section {
            display: none;
        }

        .content-section.active {
            display: block;
            animation: fadeIn 0.5s;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* LEARNING OBJECTIVES */
        .objective-block {
            margin-bottom: 40px;
            padding: 25px;
            background: #f8f9fa;
            border-radius: 12px;
            border-left: 5px solid #667eea;
        }

        .objective-block h3 {
            color: #667eea;
            font-size: 1.3em;
            margin-bottom: 15px;
            font-weight: 700;
        }

        .answer-content {
            background: white;
            padding: 20px;
            border-radius: 8px;
            line-height: 1.8;
        }

        .answer-content strong:first-of-type {
            color: #764ba2;
            font-size: 1.1em;
        }

        /* HIGHLIGHTS */
        .highlight-green {
            background: linear-gradient(135deg, #e8f5e9 0%, #c8e6c9 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #4caf50;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #1b5e20;
        }

        .highlight-purple {
            background: linear-gradient(135deg, #f3e5f5 0%, #e1bee7 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #9c27b0;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #4a148c;
        }

        .highlight-blue {
            background: linear-gradient(135deg, #e3f2fd 0%, #bbdefb 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #2196f3;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #0d47a1;
        }

        .highlight-red {
            background: linear-gradient(135deg, #ffebee 0%, #ffcdd2 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #f44336;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #b71c1c;
        }

        .highlight-yellow {
            background: linear-gradient(135deg, #fff8e1 0%, #ffecb3 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #ffc107;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #f57f17;
        }

        .highlight-teal {
            background: linear-gradient(135deg, #e0f2f1 0%, #b2dfdb 100%);
            padding: 5px 8px;
            border-radius: 4px;
            border-left: 3px solid #009688;
            display: inline-block;
            margin: 2px 0;
            font-weight: 600;
            color: #004d40;
        }

        /* COMPARISON TABLES */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
            border-radius: 8px;
            overflow: hidden;
        }

        .comparison-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }

        .comparison-table th {
            padding: 15px;
            text-align: left;
            font-weight: 700;
            font-size: 0.95em;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            position: sticky;
            top: 0;
            z-index: 10;
        }

        .comparison-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
            vertical-align: top;
        }

        .comparison-table tbody tr:nth-child(even) {
            background: #f8f9fa;
        }

        .comparison-table tbody tr:hover {
            background: #e3f2fd;
            transition: background 0.3s;
        }

        /* COLOR-CODED BOXES */
        .high-yield-box {
            background: linear-gradient(135deg, #e8f5e9 0%, #c8e6c9 100%);
            border-left: 5px solid #4caf50;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }

        .high-yield-box h4 {
            color: #2e7d32;
            margin-bottom: 12px;
        }

        .clinical-pearl {
            background: linear-gradient(135deg, #fff8e1 0%, #ffecb3 100%);
            border-left: 5px solid #ffc107;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }

        .clinical-pearl h4 {
            color: #f57f17;
            margin-bottom: 12px;
        }

        .critical-box {
            background: linear-gradient(135deg, #ffebee 0%, #ffcdd2 100%);
            border-left: 5px solid #f44336;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }

        .critical-box h4 {
            color: #c62828;
            margin-bottom: 12px;
        }

        /* HIGH-YIELD SUMMARY BOXES */
        .highlight-box {
            background: linear-gradient(135deg, #f3e5f5 0%, #e1bee7 100%);
            padding: 25px;
            margin: 25px 0;
            border-radius: 12px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .highlight-box h3 {
            color: #4a148c;
            margin-bottom: 20px;
            font-size: 1.5em;
            text-align: center;
        }

        .highlight-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .highlight-card {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        }

        .highlight-card h4 {
            color: #667eea;
            margin-bottom: 15px;
            font-size: 1.1em;
        }

        .highlight-card ul {
            list-style: none;
            padding: 0;
        }

        .highlight-card li {
            padding: 8px 0;
            line-height: 1.6;
        }

        /* MOBILE RESPONSIVE */
        @media (max-width: 768px) {
            .container {
                padding: 15px;
            }
            
            h1 {
                font-size: 1.8em;
            }
            
            .main-tabs {
                flex-direction: column;
            }
            
            .main-tab {
                width: 100%;
            }
            
            .tabs {
                flex-direction: column;
            }
            
            .tab {
                width: 100%;
            }
            
            .comparison-table {
                font-size: 0.85em;
            }
            
            .comparison-table th,
            .comparison-table td {
                padding: 10px;
            }
            
            .highlight-grid {
                grid-template-columns: 1fr;
            }
        }

        /* PRINT STYLES */
        @media print {
            body {
                background: white;
                padding: 0;
            }
            
            .container {
                box-shadow: none;
                padding: 0;
            }
            
            .main-tabs,
            .tabs {
                display: none;
            }
            
            .main-section,
            .content-section {
                display: block !important;
            }
            
            .objective-block {
                page-break-inside: avoid;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>üî¨ HIV Antiretroviral Drugs Study Guide</h1>
        <p class="subtitle">Immunopharmacology | Learning Objectives & Answers<br><em>Source: 24 HIV.txt</em></p>
        
        <!-- 3 MAIN TABS -->
        <div class="main-tabs">
            <button class="main-tab active" onclick="showMainSection('objectives')">üìù Learning Objectives</button>
            <button class="main-tab" onclick="showMainSection('summary')">‚ö° High-Yield Summary</button>
            <button class="main-tab" onclick="showMainSection('comparisons')">üìä Master Comparison Tables</button>
        </div>
        
        <!-- TAB 1: LEARNING OBJECTIVES -->
        <div id="objectives-section" class="main-section active">
            <h2>üìù Learning Objectives & Detailed Answers</h2>
            
            <div class="tabs">
                <button class="tab active" onclick="switchTab('lifecycle')">HIV Life Cycle (LO1-2)</button>
                <button class="tab" onclick="switchTab('nrtis')">NRTIs (LO3-4)</button>
                <button class="tab" onclick="switchTab('nnrtis')">NNRTIs (LO5-6)</button>
                <button class="tab" onclick="switchTab('pis')">Protease Inhibitors (LO7-11)</button>
                <button class="tab" onclick="switchTab('other')">Fusion & Integrase Inhibitors (LO12-13)</button>
            </div>
            
            <div id="lifecycle" class="content-section active">
                <div class="objective-block">
                    <h3>Learning Objective 1: Be able to discuss the life cycle of HIV, and recognize that HIV is a retrovirus (RNA) that requires reverse transcriptase to form DNA which can then integrate into host DNA.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>HIV is a <span class="highlight-red">retrovirus (RNA virus)</span> that requires reverse transcriptase to replicate. The HIV life cycle consists of seven critical steps:</p>
                        
                        <p><strong>1. Binding (Attachment):</strong> HIV binds to CD4 cell receptors and co-receptors (CCR5 or CXCR4)</p>
                        <p><strong>2. Fusion:</strong> HIV envelope and CD4 membrane fuse, allowing viral entry</p>
                        <p><strong>3. Reverse Transcription:</strong> <span class="highlight-green">HIV releases reverse transcriptase to convert viral RNA into HIV DNA</span></p>
                        <p><strong>4. Integration:</strong> HIV uses integrase enzyme to insert viral DNA into host cell DNA</p>
                        <p><strong>5. Replication:</strong> HIV uses CD4 cell machinery to make long chains of HIV proteins</p>
                        <p><strong>6. Assembly:</strong> New viral proteins and HIV RNA move to cell surface and assemble</p>
                        <p><strong>7. Budding:</strong> Newly formed immature HIV pushes out of host CD4 cell, releases protease for maturation</p>
                        
                        <div class="high-yield-box">
                            <h4>üéØ High-Yield: Drug Target Points</h4>
                            <ul>
                                <li><strong>Entry/Fusion:</strong> CCR5 antagonists (maraviroc), fusion inhibitors (enfuvirtide)</li>
                                <li><strong>Reverse Transcription:</strong> NRTIs and NNRTIs</li>
                                <li><strong>Integration:</strong> Integrase inhibitors (dolutegravir)</li>
                                <li><strong>Maturation:</strong> Protease inhibitors (darunavir)</li>
                            </ul>
                        </div>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearl</h4>
                            <p><span class="highlight-yellow">Key distinction:</span> HIV is an RNA virus that must convert its genetic material to DNA using reverse transcriptase - this unique step is absent in human cells, making it an ideal drug target.</p>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 2: Recognize that the treatment of HIV requires multiple antiretroviral drugs.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>HIV treatment requires <span class="highlight-purple">combination therapy</span> known as HAART (Highly Active Antiretroviral Therapy) to prevent resistance and achieve viral suppression.</p>
                        
                        <p><strong>Standard HAART Regimen for Treatment-Naive Patients:</strong></p>
                        <ul>
                            <li><span class="highlight-green">Two nucleoside reverse transcriptase inhibitors (NRTIs)</span> PLUS</li>
                            <li>One additional drug from:
                                <ul>
                                    <li>An integrase strand transfer inhibitor (INSTI), OR</li>
                                    <li>A non-nucleoside reverse transcriptase inhibitor (NNRTI), OR</li>
                                    <li>A protease inhibitor (PI) + pharmacoenhancer</li>
                                </ul>
                            </li>
                        </ul>
                        
                        <p><strong>Why Combination Therapy is Essential:</strong></p>
                        <ul>
                            <li>Decreases viral load more effectively</li>
                            <li>Prevents or delays resistance development</li>
                            <li>Can produce remission in some patients</li>
                            <li>Drugs do NOT eradicate the virus - lifelong therapy required</li>
                        </ul>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è CRITICAL: Monotherapy is Never Used</h4>
                            <ul>
                                <li><strong>Rapid resistance develops with single drug therapy</strong></li>
                                <li><strong>Combination therapy is the standard of care</strong></li>
                                <li><strong>Pre-exposure prophylaxis (PrEP):</strong> Daily HIV medicines for high-risk individuals</li>
                                <li><strong>Post-exposure prophylaxis (PEP):</strong> Must start within 72 hours of exposure</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
            
            <div id="nrtis" class="content-section">
                <div class="objective-block">
                    <h3>Learning Objective 3: Be familiar with Nucleoside Reverse Transcriptase Inhibitor (NRTIs) class of retroviral drugs and their common mechanism of action (but difference in which nucleotide they are an analogue for), adverse side effects</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>NRTIs are <span class="highlight-blue">nucleoside analogues</span> that require phosphorylation (x3) to become active. They work by being incorporated into viral DNA, causing chain termination.</p>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>NRTI Drug</th>
                                    <th>Nucleotide Analogue</th>
                                    <th>Key Features</th>
                                    <th>Special Uses</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Tenofovir (Viread)</strong></td>
                                    <td><span class="highlight-purple">Adenosine</span></td>
                                    <td>First-line for naive patients<br>Combined with emtricitabine as Truvada</td>
                                    <td>PrEP<br>HBV monotherapy</td>
                                </tr>
                                <tr>
                                    <td><strong>Emtricitabine (Emtriva)</strong></td>
                                    <td><span class="highlight-purple">Cytosine</span></td>
                                    <td>Part of Truvada<br>Well tolerated</td>
                                    <td>First-line therapy<br>PrEP</td>
                                </tr>
                                <tr>
                                    <td><strong>Lamivudine (Epivir)</strong></td>
                                    <td><span class="highlight-purple">Cytosine</span></td>
                                    <td>Very effective, low toxicity<br>Safe in pregnancy</td>
                                    <td>HBV monotherapy</td>
                                </tr>
                                <tr>
                                    <td><strong>Abacavir (Ziagen)</strong></td>
                                    <td><span class="highlight-purple">Guanosine</span></td>
                                    <td>Screen HLA-B*5701 first<br>Fatal hypersensitivity possible</td>
                                    <td>Only if HLA-B*5701 negative</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Common Mechanism of Action</h4>
                            <ul>
                                <li><strong>Step 1:</strong> Drug enters cell as nucleoside analogue</li>
                                <li><strong>Step 2:</strong> Undergoes triple phosphorylation by cellular kinases</li>
                                <li><strong>Step 3:</strong> Incorporated into growing viral DNA strand by reverse transcriptase</li>
                                <li><strong>Step 4:</strong> <span class="highlight-red">Chain termination</span> - lacks 3'-OH group for next nucleotide</li>
                            </ul>
                            <br>
                            <p><strong>üß† NRTI Memory Tricks:</strong></p>
                            <ul>
                                <li><strong>"TALE" of NRTIs:</strong>
                                    <ul>
                                        <li><strong>T</strong>enofovir - <strong>A</strong>denosine analogue</li>
                                        <li><strong>A</strong>bacavir - Gu<strong>A</strong>nosine analogue</li>
                                        <li><strong>L</strong>amivudine - Cytosine ana<strong>L</strong>ogue</li>
                                        <li><strong>E</strong>mtricitabine - Cytosin<strong>E</strong> analogue</li>
                                    </ul>
                                </li>
                                <li><strong>Remember Abacavir screening:</strong> "A-BAD-CAVIR reaction if HLA-B*5701 positive"</li>
                                <li><strong>Truvada components:</strong> "TE" = <strong>T</strong>enofovir + <strong>E</strong>mtricitabine</li>
                            </ul>
                        </div>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è Common Serious Side Effects - All NRTIs</h4>
                            <ul>
                                <li><strong><span class="highlight-red">Lactic acidosis</span></strong> - rare but serious</li>
                                <li><strong><span class="highlight-red">Hepatotoxicity</span></strong> - monitor liver function</li>
                                <li>Higher risk if: obese, previous liver disease, prolonged use</li>
                                <li>Risk factors: Female, pregnancy, obesity, poor liver function, low CD4 count</li>
                            </ul>
                            <br>
                            <p><strong>üß† Memory Aid - "NRTI = No 3'-OH Results in Termination Immediately"</strong></p>
                            <p><strong>Remember NRTI toxicity - "LACTIC":</strong></p>
                            <ul>
                                <li><strong>L</strong>actic acidosis</li>
                                <li><strong>A</strong>ll NRTIs can cause it</li>
                                <li><strong>C</strong>heck liver function</li>
                                <li><strong>T</strong>oxicity increases with obesity</li>
                                <li><strong>I</strong>ncreased risk in pregnancy</li>
                                <li><strong>C</strong>D4 low = higher risk</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 4: Recognize that NRTIs have both drug-specific and common adverse side effects.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Drug</th>
                                    <th>Drug-Specific Side Effects</th>
                                    <th>Common NRTI Side Effects</th>
                                    <th>Critical Warnings</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Tenofovir</strong></td>
                                    <td>GI disturbances<br>Flatulence</td>
                                    <td rowspan="4">All NRTIs can cause:<br>‚Ä¢ Lactic acidosis<br>‚Ä¢ Hepatotoxicity<br>‚Ä¢ Mitochondrial toxicity</td>
                                    <td>Monitor renal function</td>
                                </tr>
                                <tr>
                                    <td><strong>Emtricitabine</strong></td>
                                    <td>GI disturbances<br>Generally well tolerated</td>
                                    <td>Part of Truvada combination</td>
                                </tr>
                                <tr>
                                    <td><strong>Lamivudine</strong></td>
                                    <td>Headache, fatigue<br>Insomnia, GI<br><span class="highlight-green">Safe in pregnancy</span></td>
                                    <td>Very low toxicity profile</td>
                                </tr>
                                <tr>
                                    <td><strong>Abacavir</strong></td>
                                    <td><span class="highlight-red">Hypersensitivity (5%)</span><br>Fever, rash, respiratory symptoms<br>N/V/D</td>
                                    <td><span class="highlight-red">NEVER restart if hypersensitivity - can be FATAL!</span><br>Must screen HLA-B*5701</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearl</h4>
                            <p><strong>Abacavir Hypersensitivity:</strong> If patient develops fever, malaise, skin rash, chills, sore throat, or difficulty breathing - <span class="highlight-red">DISCONTINUE IMMEDIATELY and NEVER RESTART</span>. Restarting after hypersensitivity reaction can be fatal!</p>
                        </div>
                    </div>
                </div>
            </div>
            
            <div id="nnrtis" class="content-section">
                <div class="objective-block">
                    <h3>Learning Objective 5: Be familiar with the NNRTIs, and how their mechanism of action is different than NRTIs.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>NNRTIs work by a <span class="highlight-purple">completely different mechanism</span> than NRTIs:</p>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Feature</th>
                                    <th>NRTIs</th>
                                    <th>NNRTIs</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Mechanism</strong></td>
                                    <td>Nucleoside analogues<br>Incorporated into DNA<br>Chain termination</td>
                                    <td><span class="highlight-green">Bind directly to reverse transcriptase</span><br>Allosteric inhibition<br>Block enzyme activity</td>
                                </tr>
                                <tr>
                                    <td><strong>Activation Required</strong></td>
                                    <td>YES - require phosphorylation (x3)</td>
                                    <td><span class="highlight-yellow">NO - active without phosphorylation</span></td>
                                </tr>
                                <tr>
                                    <td><strong>Binding Site</strong></td>
                                    <td>Compete with natural nucleotides</td>
                                    <td>Bind to pocket in reverse transcriptase</td>
                                </tr>
                                <tr>
                                    <td><strong>Resistance</strong></td>
                                    <td>Develops slowly</td>
                                    <td><span class="highlight-red">Rapid resistance if used alone</span></td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <p><strong>NNRTI Drugs:</strong></p>
                        <ul>
                            <li><strong>Rilpivirine (Edurant)</strong></li>
                            <li><strong>Doravirine (Pifeltro)</strong></li>
                        </ul>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Key Mechanism Difference</h4>
                            <p>NNRTIs bind to a hydrophobic pocket near the active site of reverse transcriptase, causing conformational change that blocks DNA polymerization. They do NOT need to be incorporated into the growing DNA chain like NRTIs.</p>
                            <br>
                            <p><strong>üß† Memory Trick - "NRTIs vs NNRTIs":</strong></p>
                            <ul>
                                <li><strong>NRTIs = "Needs"</strong>
                                    <ul>
                                        <li><strong>N</strong>ucleotide analogue</li>
                                        <li><strong>E</strong>nters DNA chain</li>
                                        <li><strong>E</strong>nds chain (termination)</li>
                                        <li><strong>D</strong>epends on phosphorylation</li>
                                        <li><strong>S</strong>low resistance</li>
                                    </ul>
                                </li>
                                <li><strong>NNRTIs = "No Need"</strong>
                                    <ul>
                                        <li><strong>No</strong> phosphorylation required</li>
                                        <li><strong>No</strong> incorporation into DNA</li>
                                        <li><strong>N</strong>on-competitive inhibition</li>
                                        <li><strong>E</strong>asy (rapid) resistance</li>
                                        <li><strong>E</strong>xternal binding site</li>
                                        <li><strong>D</strong>irect enzyme binding</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearl</h4>
                            <p>NNRTIs must always be used in combination with NRTIs - <span class="highlight-red">rapid resistance develops if used alone</span>.</p>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 6: Recall which NNRTI is teratogenic, and which NNRTI is safe in pregnancy.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>[Information not provided in source material regarding teratogenic NNRTIs or pregnancy safety]</p>
                        
                        <p><strong>Available NNRTI Side Effect Information:</strong></p>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Drug</th>
                                    <th>Route</th>
                                    <th>Adverse Effects</th>
                                    <th>Special Considerations</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Rilpivirine (Edurant)</strong></td>
                                    <td>Oral</td>
                                    <td>‚Ä¢ Depression<br>‚Ä¢ Increased cholesterol<br>‚Ä¢ Headache</td>
                                    <td>Not recommended with hepatitis co-infection (increases liver enzymes)</td>
                                </tr>
                                <tr>
                                    <td><strong>Doravirine (Pifeltro)</strong></td>
                                    <td>Oral</td>
                                    <td>‚Ä¢ CNS: headache, fatigue<br>‚Ä¢ Cardiovascular effects<br>‚Ä¢ GI disturbances<br>‚Ä¢ Rash</td>
                                    <td>-</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Note</h4>
                            <p>Cabenuva (approved January 2021) combines <strong>cabotegravir</strong> (integrase inhibitor) with <strong>rilpivirine</strong> (NNRTI) as the first extended-release injectable HIV treatment (monthly or bimonthly).</p>
                        </div>
                    </div>
                </div>
            </div>
            
            <div id="pis" class="content-section">
                <div class="objective-block">
                    <h3>Learning Objective 7: Recall the drugs that comprise the Protease Inhibitor class of antiretrovirals, and their common mechanism of action.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p><strong>Protease Inhibitor Drugs:</strong></p>
                        <ul>
                            <li><strong>Darunavir (Prezista)</strong> - <span class="highlight-green">Drug of first choice when PI included</span></li>
                            <li><strong>Atazanavir (Reyataz)</strong> - Drug of second choice</li>
                            <li><strong>Ritonavir (Norvir)</strong> - <span class="highlight-purple">Pharmacoenhancer</span></li>
                            <li><strong>Cobicistat (Tybost)</strong> - <span class="highlight-purple">Pharmacoenhancer</span></li>
                        </ul>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Common Mechanism of Action</h4>
                            <p><strong>MOA:</strong> PIs bind to HIV protease enzyme, inhibiting its function of digesting long viral polypeptides into smaller, mature functional proteins. Without protease activity:</p>
                            <ul>
                                <li>Viral particles cannot mature</li>
                                <li>Individual core proteins are not released</li>
                                <li>Viruses remain non-infectious</li>
                            </ul>
                        </div>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Key Concept</h4>
                            <p>Protease inhibitors work at the <span class="highlight-yellow">final step of viral maturation</span> - preventing the conversion of immature viral particles into infectious virions.</p>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 8: Recognize the common adverse effects and common pharmacokinetics of PIs and the potential for drug interactions that will influence the metabolism of protease inhibitors.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è Common Adverse Effects - All PIs</h4>
                            <ul>
                                <li><strong><span class="highlight-red">Altered body fat distribution</span>:</strong> Buffalo hump, truncal obesity, facial/peripheral atrophy</li>
                                <li><strong>Insulin resistance</strong> and hyperglycemia</li>
                                <li><strong>Increased serum cholesterol</strong> (use pitavastatin or pravastatin if statin needed)</li>
                                <li><strong>Spontaneous bleeding</strong> in hemophilia A or B patients</li>
                            </ul>
                            <br>
                            <p><strong>üß† Memory Trick - PI Side Effects "BICS":</strong></p>
                            <ul>
                                <li><strong>B</strong>uffalo hump & body fat changes</li>
                                <li><strong>I</strong>nsulin resistance (diabetes)</li>
                                <li><strong>C</strong>holesterol elevation</li>
                                <li><strong>S</strong>pontaneous bleeding</li>
                            </ul>
                        </div>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Common Pharmacokinetics</h4>
                            <ul>
                                <li>Route: Oral administration</li>
                                <li><strong><span class="highlight-purple">All PIs are metabolized by CYP3A4</span></strong></li>
                                <li>Often given with ritonavir or cobicistat (CYP3A4 inhibitors) to:
                                    <ul>
                                        <li>Increase PI blood levels</li>
                                        <li>Allow lower doses</li>
                                        <li>Less frequent dosing</li>
                                    </ul>
                                </li>
                                <li>Mutations and resistance common if used alone - must combine with NRTIs</li>
                            </ul>
                            <br>
                            <p><strong>üß† Memory Tricks for PIs:</strong></p>
                            <ul>
                                <li><strong>"All -navirs end in NAVIR"</strong> (easy to identify PIs)</li>
                                <li><strong>"DARUN away from sulfa"</strong> - Darunavir contraindicated with sulfa allergy</li>
                                <li><strong>"RITA boosts"</strong> - Ritonavir is the booster</li>
                                <li><strong>"St. John's WARTS your treatment"</strong> - St. John's Wort ruins (warts) PI therapy</li>
                                <li><strong>Remember PI metabolism:</strong> "3A4 PIs" = CYP3A4 metabolizes all PIs</li>
                            </ul>
                        </div>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Drug Interaction Type</th>
                                    <th>Effect on PIs</th>
                                    <th>Examples</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>CYP3A4 Inducers</strong></td>
                                    <td><span class="highlight-red">Decrease PI levels</span></td>
                                    <td>Rifampin, phenytoin, phenobarbital, carbamazepine</td>
                                </tr>
                                <tr>
                                    <td><strong>CYP3A4 Inhibitors</strong></td>
                                    <td><span class="highlight-green">Increase PI levels</span></td>
                                    <td>Ritonavir, cobicistat (used therapeutically)</td>
                                </tr>
                                <tr>
                                    <td><strong>Contraindicated</strong></td>
                                    <td>Severe interaction</td>
                                    <td><span class="highlight-red">St. John's Wort - NEVER use (increases PI metabolism)</span></td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearl</h4>
                            <p>Drug-to-drug interactions are a <span class="highlight-yellow">key challenge in HIV/TB co-infection</span>, as TB treatments (especially rifampin) can significantly impact effectiveness of HIV medicines.</p>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 9: Describe the use of ritonavir (Norvir) in HIV therapy, and why it should (or shouldn't) be prescribed with other PIs.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p>Ritonavir has a unique role as a <span class="highlight-purple">pharmacokinetic enhancer or "booster"</span> in HIV therapy.</p>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Why Ritonavir SHOULD Be Used with Other PIs</h4>
                            <ul>
                                <li><strong>MOA:</strong> Potent CYP3A4 inhibitor</li>
                                <li><strong>Effect:</strong> Increases bioavailability of other PIs by decreasing their metabolism</li>
                                <li><strong>Benefits:</strong>
                                    <ul>
                                        <li>Permits less frequent dosing (once daily instead of multiple times)</li>
                                        <li>Allows lower doses of the primary PI</li>
                                        <li>Greater antiviral activity</li>
                                        <li>Improves patient compliance</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Pharmacoenhancer</th>
                                    <th>Mechanism</th>
                                    <th>Advantages</th>
                                    <th>Disadvantages</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Ritonavir (Norvir)</strong></td>
                                    <td>CYP3A4 inhibitor<br>Also has PI activity</td>
                                    <td>Boosts all PIs<br>Can boost elvitegravir (INSTI)</td>
                                    <td>‚Ä¢ PI side effects<br>‚Ä¢ Contains ethanol<br>‚Ä¢ Many drug interactions</td>
                                </tr>
                                <tr>
                                    <td><strong>Cobicistat (Tybost)</strong></td>
                                    <td>CYP3A4 inhibitor<br>NO PI activity</td>
                                    <td>No PI side effects<br>Pure booster</td>
                                    <td>‚Ä¢ CYP drug interactions only<br>‚Ä¢ Hepatic effects</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è Important Ritonavir Warnings</h4>
                            <ul>
                                <li><strong>Formulation contains ethanol</strong> - do NOT give with metronidazole or cephalosporins (disulfiram-like reaction)</li>
                                <li><strong>Adverse effects:</strong> GI (vomiting, weakness, diarrhea), burning, tingling, elevated liver enzymes</li>
                                <li><strong>Multiple drug interactions</strong> due to CYP3A4 inhibition</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 10: Discuss why you wouldn't use two PIs in individuals with sulfonamide hypersensitivities.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p><span class="highlight-red">Darunavir (Prezista) contains a sulfonamide moiety</span> and must not be used in patients with sulfonamide allergy.</p>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è CRITICAL: Sulfonamide Contraindication</h4>
                            <p><strong>Darunavir (Prezista):</strong></p>
                            <ul>
                                <li>Contains sulfonamide structure</li>
                                <li><span class="highlight-red">Absolutely contraindicated in sulfa-allergic patients</span></li>
                                <li>Can cause severe hypersensitivity reactions</li>
                                <li>This is the primary PI of choice, so alternatives must be used</li>
                            </ul>
                        </div>
                        
                        <p><strong>Note:</strong> The source material doesn't specify which other PI contains sulfonamide, but darunavir is clearly identified as having this issue. In sulfa-allergic patients, atazanavir would be the alternative PI choice.</p>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 11: Recall the specific adverse side effects associated with each PI.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Protease Inhibitor</th>
                                    <th>Specific Adverse Effects</th>
                                    <th>Special Considerations</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Darunavir<br>(Prezista)</strong></td>
                                    <td>‚Ä¢ Rash, N/V/D (most common)<br>‚Ä¢ Headache, nightmares<br>‚Ä¢ <span class="highlight-red">Sulfonamide allergy risk</span></td>
                                    <td>‚Ä¢ <span class="highlight-green">Safer and more effective than other PIs</span><br>‚Ä¢ First choice PI<br>‚Ä¢ Must take with food (needs acid)</td>
                                </tr>
                                <tr>
                                    <td><strong>Atazanavir<br>(Reyataz)</strong></td>
                                    <td>‚Ä¢ <span class="highlight-yellow">Increased bilirubin</span> (inhibits UGT1A1)<br>‚Ä¢ Rash, diarrhea, nausea<br>‚Ä¢ Hyperglycemia<br>‚Ä¢ <span class="highlight-green">Less body fat changes</span></td>
                                    <td>‚Ä¢ Second choice PI<br>‚Ä¢ Once daily<br>‚Ä¢ Take with light meal</td>
                                </tr>
                                <tr>
                                    <td><strong>Ritonavir<br>(Norvir)</strong></td>
                                    <td>‚Ä¢ GI: vomiting, weakness, diarrhea<br>‚Ä¢ Burning, tingling<br>‚Ä¢ Elevated liver enzymes<br>‚Ä¢ Nausea</td>
                                    <td>‚Ä¢ Used as booster<br>‚Ä¢ <span class="highlight-red">Contains ethanol</span><br>‚Ä¢ Many drug interactions</td>
                                </tr>
                                <tr>
                                    <td><strong>Cobicistat<br>(Tybost)</strong></td>
                                    <td>‚Ä¢ Hepatic effects<br>‚Ä¢ CNS: headache, dreams<br>‚Ä¢ Rash</td>
                                    <td>‚Ä¢ Pure booster (no PI activity)<br>‚Ä¢ CYP drug interactions</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearls</h4>
                            <ul>
                                <li><strong>Darunavir:</strong> Despite being first choice, avoid in sulfa allergy</li>
                                <li><strong>Atazanavir:</strong> Causes cosmetic jaundice but is benign - counsel patients</li>
                                <li><strong>All PIs:</strong> Monitor for lipodystrophy syndrome and metabolic changes</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
            
            <div id="other" class="content-section">
                <div class="objective-block">
                    <h3>Learning Objective 12: Explain the unique mechanism of action for Fusion Inhibitors, recall the two drugs in this class, and when these drugs should be used.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p><strong>Fusion Inhibitor Drugs:</strong></p>
                        <ul>
                            <li><strong>Enfuvirtide (Fuzeon)</strong> - targets gp41</li>
                            <li><strong>Maraviroc (Selzentry)</strong> - targets CCR5 receptor</li>
                            <li><strong>Fostemsavir (Rukobia)</strong> - targets gp120</li>
                            <li><strong>Ibalizumab (Trogarzo)</strong> - targets CD4 receptor</li>
                        </ul>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Drug</th>
                                    <th>Unique Mechanism</th>
                                    <th>Administration</th>
                                    <th>When to Use</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Enfuvirtide</strong></td>
                                    <td>Binds to <span class="highlight-purple">gp41 subunit</span><br>Prevents conformational change for membrane fusion</td>
                                    <td>Subcutaneous injection<br>(inconvenient, expensive)</td>
                                    <td>‚Ä¢ Advanced disease<br>‚Ä¢ Treatment-experienced<br>‚Ä¢ Ongoing viral replication</td>
                                </tr>
                                <tr>
                                    <td><strong>Maraviroc</strong></td>
                                    <td>Binds to <span class="highlight-purple">CCR5 receptor</span> on CD4 T-cells<br>Blocks viral entry</td>
                                    <td>Oral</td>
                                    <td>‚Ä¢ <span class="highlight-red">ONLY CCR5-tropic HIV</span><br>‚Ä¢ Treatment failure<br>‚Ä¢ Must test tropism first</td>
                                </tr>
                                <tr>
                                    <td><strong>Fostemsavir</strong></td>
                                    <td>Binds to <span class="highlight-purple">gp120 subunit</span><br>Prevents CD4 interaction</td>
                                    <td>Oral prodrug</td>
                                    <td>‚Ä¢ Treatment-resistant patients<br>‚Ä¢ Approved 2020</td>
                                </tr>
                                <tr>
                                    <td><strong>Ibalizumab</strong></td>
                                    <td>Binds to <span class="highlight-purple">CD4 receptor</span><br>Blocks conformational changes</td>
                                    <td>IV every 2 weeks<br>(long-acting)</td>
                                    <td>‚Ä¢ Both CCR5 and CXCR4 strains<br>‚Ä¢ Treatment failure<br>‚Ä¢ Combined therapy</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Key Concept: Entry/Fusion Inhibition</h4>
                            <p>These drugs prevent HIV from entering CD4 cells by blocking different steps:</p>
                            <ul>
                                <li><strong>Attachment:</strong> Fostemsavir (gp120), Ibalizumab (CD4)</li>
                                <li><strong>Co-receptor binding:</strong> Maraviroc (CCR5)</li>
                                <li><strong>Fusion:</strong> Enfuvirtide (gp41)</li>
                            </ul>
                            <br>
                            <p><strong>üß† Memory Trick - "FIME blocks HIV TIME":</strong></p>
                            <ul>
                                <li><strong>F</strong>ostemsavir - gp120</li>
                                <li><strong>I</strong>balizumab - CD4</li>
                                <li><strong>M</strong>araviroc - CCR5</li>
                                <li><strong>E</strong>nfuvirtide - gp41</li>
                            </ul>
                            <p><strong>Remember fusion proteins: "41 + 120 = 161" (gp41 + gp120 = gp160 precursor)</strong></p>
                        </div>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è Important: Tropism Testing</h4>
                            <p><strong>Maraviroc:</strong> <span class="highlight-red">MUST test for CCR5 tropism before use</span>. Will NOT work for CXCR4 or mixed tropism HIV strains.</p>
                        </div>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Use Pattern</h4>
                            <p>Fusion inhibitors are typically reserved for <span class="highlight-yellow">treatment-experienced patients with resistance</span> to other drug classes, not first-line therapy.</p>
                        </div>
                    </div>
                </div>
                
                <div class="objective-block">
                    <h3>Learning Objective 13: Discuss the mechanism of action for Dolutegravir, an integrase inhibitor, and its importance in treating treatment-resistant patients.</h3>
                    <div class="answer-content">
                        <strong>Answer:</strong>
                        <p><strong>Integrase Inhibitors:</strong></p>
                        <ul>
                            <li><strong>Dolutegravir (Tivicay)</strong></li>
                            <li><strong>Cabotegravir (Vocabria)</strong></li>
                            <li><strong>Bictegravir</strong></li>
                        </ul>
                        
                        <div class="high-yield-box">
                            <h4>üéØ Mechanism of Action - Dolutegravir</h4>
                            <p><strong>MOA:</strong> <span class="highlight-green">Blocks the integrase enzyme</span> needed for replication by inhibiting the strand transfer step of viral DNA integration into host cell DNA.</p>
                            <ul>
                                <li>Prevents viral DNA from becoming part of host chromosome</li>
                                <li>Viral DNA remains linear and unintegrated</li>
                                <li>Cannot produce new viral proteins</li>
                                <li>Typically used in combination with NRTIs</li>
                            </ul>
                        </div>
                        
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Integrase Inhibitor</th>
                                    <th>Administration</th>
                                    <th>Key Features</th>
                                    <th>Adverse Effects</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Dolutegravir<br>(Tivicay)</strong></td>
                                    <td>Oral</td>
                                    <td>‚Ä¢ High barrier to resistance<br>‚Ä¢ Once daily dosing<br>‚Ä¢ First-line option</td>
                                    <td>Headache, insomnia, GI<br>Hyperglycemia<br>Hepatitis (rare)</td>
                                </tr>
                                <tr>
                                    <td><strong>Cabotegravir<br>(Vocabria)</strong></td>
                                    <td>Oral, IM</td>
                                    <td>‚Ä¢ Part of Cabenuva<br>‚Ä¢ Monthly/bimonthly injection</td>
                                    <td>Rash, depression<br>Headache, insomnia</td>
                                </tr>
                                <tr>
                                    <td><strong>Bictegravir</strong></td>
                                    <td>Oral</td>
                                    <td>‚Ä¢ Part of Biktarvy<br>‚Ä¢ Complete single-tablet regimen</td>
                                    <td>Nephrotoxicity<br>Lactic acidosis<br>Hepatotoxicity</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <div class="critical-box">
                            <h4>‚ö†Ô∏è Importance for Treatment-Resistant Patients</h4>
                            <ul>
                                <li><strong>High genetic barrier to resistance</strong> - requires multiple mutations</li>
                                <li><strong>Different mechanism</strong> - works when RT or PI resistance present</li>
                                <li><strong>Potent activity</strong> - rapid viral suppression</li>
                                <li><strong>Well-tolerated</strong> - fewer side effects than older drugs</li>
                                <li><strong>Now preferred first-line</strong> - shifted from salvage to initial therapy</li>
                            </ul>
                        </div>
                        
                        <div class="clinical-pearl">
                            <h4>üíé Clinical Pearls</h4>
                            <ul>
                                <li><strong>Biktarvy:</strong> Complete regimen = bictegravir + emtricitabine + tenofovir (once daily pill)</li>
                                <li><strong>Cabenuva:</strong> First long-acting injectable (cabotegravir + rilpivirine) for maintenance therapy</li>
                                <li><strong>INSTIs are now preferred</strong> for most treatment-naive patients due to efficacy and tolerability</li>
                            </ul>
                            <br>
                            <p><strong>üß† Memory Tricks for Integrase Inhibitors:</strong></p>
                            <ul>
                                <li><strong>All end in "-TEGRAVIR"</strong> (easy to identify)</li>
                                <li><strong>"DOLT"</strong> = <strong>DOL</strong>u<strong>T</strong>egravir is tough (high barrier to resistance)</li>
                                <li><strong>"BIKE-tarvy"</strong> = Biktarvy is a complete ride (complete single-tablet regimen)</li>
                                <li><strong>"CAB-NEW-VA"</strong> = Cabenuva is the NEW injectable VAccine-like treatment (monthly shots)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- TAB 2: HIGH-YIELD SUMMARY -->
        <div id="summary-section" class="main-section">
            <h2>‚ö° High-Yield Summary - Must-Know Facts</h2>
            
            <h3>üéØ Drug Classes & Mechanisms</h3>
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Drug Class</th>
                        <th>Mechanism</th>
                        <th>Key Drugs</th>
                        <th>Must-Know Facts</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>NRTIs</strong></td>
                        <td>Nucleoside analogues<br>Chain termination</td>
                        <td>Tenofovir, Emtricitabine<br>Lamivudine, Abacavir</td>
                        <td><span class="highlight-red">All cause lactic acidosis & hepatotoxicity</span><br>Abacavir: Screen HLA-B*5701</td>
                    </tr>
                    <tr>
                        <td><strong>NNRTIs</strong></td>
                        <td>Direct RT binding<br>No phosphorylation needed</td>
                        <td>Rilpivirine, Doravirine</td>
                        <td><span class="highlight-yellow">Rapid resistance if used alone</span></td>
                    </tr>
                    <tr>
                        <td><strong>PIs</strong></td>
                        <td>Block protease<br>Prevent maturation</td>
                        <td>Darunavir (1st choice)<br>Atazanavir (2nd choice)</td>
                        <td><span class="highlight-purple">All metabolized by CYP3A4</span><br>Lipodystrophy syndrome</td>
                    </tr>
                    <tr>
                        <td><strong>INSTIs</strong></td>
                        <td>Block DNA integration</td>
                        <td>Dolutegravir, Bictegravir<br>Cabotegravir</td>
                        <td><span class="highlight-green">Now preferred first-line</span><br>High barrier to resistance</td>
                    </tr>
                    <tr>
                        <td><strong>Entry/Fusion</strong></td>
                        <td>Block viral entry</td>
                        <td>Maraviroc (CCR5)<br>Enfuvirtide (gp41)</td>
                        <td>Reserved for resistant cases<br>Maraviroc: <span class="highlight-red">Test tropism first</span></td>
                    </tr>
                </tbody>
            </table>
            
            <div class="highlight-box">
                <h3>üî• Highest-Yield Drug Interactions</h3>
                <div class="highlight-grid">
                    <div class="highlight-card">
                        <h4>CYP3A4 & Protease Inhibitors</h4>
                        <ul>
                            <li><span class="highlight-red">St. John's Wort: NEVER use</span></li>
                            <li>Rifampin decreases PI levels</li>
                            <li>Ritonavir boosts other PIs</li>
                            <li>Watch for statin interactions</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>Contraindications</h4>
                        <ul>
                            <li><span class="highlight-red">Darunavir + sulfa allergy</span></li>
                            <li><span class="highlight-red">Abacavir if HLA-B*5701 positive</span></li>
                            <li>Ritonavir + metronidazole (contains ethanol)</li>
                            <li>Maraviroc if CXCR4 tropism</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>Special Populations</h4>
                        <ul>
                            <li>Pregnancy: Lamivudine is safe</li>
                            <li>HBV co-infection: Use tenofovir or lamivudine</li>
                            <li>TB co-infection: Major drug interactions</li>
                            <li>Renal disease: Adjust NRTI doses</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="critical-box">
                <h4>‚ö†Ô∏è Never Forget: Life-Threatening Reactions</h4>
                <ul>
                    <li><strong>Abacavir hypersensitivity:</strong> <span class="highlight-red">NEVER rechallenge - can be FATAL</span></li>
                    <li><strong>Lactic acidosis (NRTIs):</strong> Higher risk in obesity, pregnancy, liver disease</li>
                    <li><strong>St. John's Wort:</strong> Causes treatment failure with PIs</li>
                    <li><strong>Immune reconstitution syndrome:</strong> Can unmask infections when starting HAART</li>
                </ul>
            </div>
            
            <div class="highlight-box" style="background: linear-gradient(135deg, #e1f5fe 0%, #b3e5fc 100%);">
                <h3>üß† Master Mnemonics & Memory Tricks</h3>
                <div class="highlight-grid">
                    <div class="highlight-card">
                        <h4>Drug Class Identification</h4>
                        <ul>
                            <li><strong>"-NAVIR"</strong> = Protease Inhibitors</li>
                            <li><strong>"-TEGRAVIR"</strong> = Integrase Inhibitors</li>
                            <li><strong>"-PINE" or "-RINE"</strong> = NNRTIs</li>
                            <li><strong>"-UDINE" or "-OVIR"</strong> = NRTIs</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>HIV Life Cycle - "BFRIRAB"</h4>
                        <ul>
                            <li><strong>B</strong>inding</li>
                            <li><strong>F</strong>usion</li>
                            <li><strong>R</strong>everse transcription</li>
                            <li><strong>I</strong>ntegration</li>
                            <li><strong>R</strong>eplication</li>
                            <li><strong>A</strong>ssembly</li>
                            <li><strong>B</strong>udding</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>HAART Components - "2+1"</h4>
                        <ul>
                            <li><strong>2</strong> NRTIs (backbone)</li>
                            <li><strong>+1</strong> from another class:</li>
                            <li>‚Ä¢ INSTI (preferred)</li>
                            <li>‚Ä¢ NNRTI</li>
                            <li>‚Ä¢ Boosted PI</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>Critical Warnings</h4>
                        <ul>
                            <li><strong>"A-BAD reaction"</strong> - Abacavir + HLA-B*5701</li>
                            <li><strong>"DARUN from sulfa"</strong> - Darunavir sulfa allergy</li>
                            <li><strong>"WART your treatment"</strong> - St. John's Wort ruins PIs</li>
                            <li><strong>"ATAZA-VEER yellow"</strong> - Atazanavir ‚Üí jaundice</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>Drug Combinations</h4>
                        <ul>
                            <li><strong>Truvada = "TE"</strong> (Tenofovir + Emtricitabine)</li>
                            <li><strong>Biktarvy = "BET"</strong> (Bictegravir + Emtricitabine + Tenofovir)</li>
                            <li><strong>Cabenuva = "CR"</strong> (Cabotegravir + Rilpivirine)</li>
                        </ul>
                    </div>
                    <div class="highlight-card">
                        <h4>Side Effect Patterns</h4>
                        <ul>
                            <li><strong>NRTIs = "LACTIC"</strong> (Lactic Acidosis Causes Toxicity In Cells)</li>
                            <li><strong>PIs = "BICS"</strong> (Buffalo hump, Insulin resistance, Cholesterol, Spontaneous bleeding)</li>
                            <li><strong>All HIV drugs = "3H"</strong> (Hepatotoxicity, Hypersensitivity, Hematologic effects)</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="high-yield-box">
                <h4>üéØ Standard HAART Regimen</h4>
                <p><strong>2 NRTIs + 1 additional drug:</strong></p>
                <ul>
                    <li><strong>Preferred backbone:</strong> Tenofovir + Emtricitabine (Truvada)</li>
                    <li><strong>Plus one of:</strong>
                        <ul>
                            <li>INSTI (preferred): Dolutegravir or Bictegravir</li>
                            <li>NNRTI: Rilpivirine or Doravirine</li>
                            <li>Boosted PI: Darunavir/ritonavir</li>
                        </ul>
                    </li>
                </ul>
            </div>
        </div>
        
        <!-- TAB 3: MASTER COMPARISON TABLES -->
        <div id="comparisons-section" class="main-section">
            <h2>üìä Master Comparison Tables</h2>
            
            <h3>Complete HIV Drug Reference</h3>
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Drug</th>
                        <th>Class</th>
                        <th>Mechanism</th>
                        <th>Key Side Effects</th>
                        <th>Critical Points</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Tenofovir</strong></td>
                        <td>NRTI</td>
                        <td>Adenosine analogue</td>
                        <td>GI, flatulence</td>
                        <td>First-line, also for HBV</td>
                    </tr>
                    <tr>
                        <td><strong>Emtricitabine</strong></td>
                        <td>NRTI</td>
                        <td>Cytosine analogue</td>
                        <td>Well tolerated</td>
                        <td>Part of Truvada</td>
                    </tr>
                    <tr>
                        <td><strong>Lamivudine</strong></td>
                        <td>NRTI</td>
                        <td>Cytosine analogue</td>
                        <td>Minimal</td>
                        <td><span class="highlight-green">Safe in pregnancy</span></td>
                    </tr>
                    <tr>
                        <td><strong>Abacavir</strong></td>
                        <td>NRTI</td>
                        <td>Guanosine analogue</td>
                        <td><span class="highlight-red">Fatal hypersensitivity</span></td>
                        <td>Screen HLA-B*5701 first</td>
                    </tr>
                    <tr>
                        <td><strong>Rilpivirine</strong></td>
                        <td>NNRTI</td>
                        <td>Direct RT inhibitor</td>
                        <td>Depression, ‚Üëcholesterol</td>
                        <td>Part of Cabenuva</td>
                    </tr>
                    <tr>
                        <td><strong>Doravirine</strong></td>
                        <td>NNRTI</td>
                        <td>Direct RT inhibitor</td>
                        <td>CNS, cardiovascular, rash</td>
                        <td>No phosphorylation needed</td>
                    </tr>
                    <tr>
                        <td><strong>Darunavir</strong></td>
                        <td>PI</td>
                        <td>Protease inhibitor</td>
                        <td>Rash, N/V/D</td>
                        <td><span class="highlight-red">Sulfa allergy contraindication</span></td>
                    </tr>
                    <tr>
                        <td><strong>Atazanavir</strong></td>
                        <td>PI</td>
                        <td>Protease inhibitor</td>
                        <td><span class="highlight-yellow">‚ÜëBilirubin</span></td>
                        <td>Less lipodystrophy</td>
                    </tr>
                    <tr>
                        <td><strong>Ritonavir</strong></td>
                        <td>PI/Booster</td>
                        <td>CYP3A4 inhibitor</td>
                        <td>GI, liver enzymes</td>
                        <td><span class="highlight-red">Contains ethanol</span></td>
                    </tr>
                    <tr>
                        <td><strong>Dolutegravir</strong></td>
                        <td>INSTI</td>
                        <td>Integrase inhibitor</td>
                        <td>Headache, insomnia</td>
                        <td><span class="highlight-green">High barrier to resistance</span></td>
                    </tr>
                    <tr>
                        <td><strong>Bictegravir</strong></td>
                        <td>INSTI</td>
                        <td>Integrase inhibitor</td>
                        <td>Nephrotoxicity</td>
                        <td>Part of Biktarvy (complete regimen)</td>
                    </tr>
                    <tr>
                        <td><strong>Maraviroc</strong></td>
                        <td>Entry Inhibitor</td>
                        <td>CCR5 antagonist</td>
                        <td>Rash</td>
                        <td><span class="highlight-red">Only for CCR5-tropic HIV</span></td>
                    </tr>
                    <tr>
                        <td><strong>Enfuvirtide</strong></td>
                        <td>Fusion Inhibitor</td>
                        <td>gp41 inhibitor</td>
                        <td>Injection site reactions</td>
                        <td>SubQ, expensive, salvage therapy</td>
                    </tr>
                </tbody>
            </table>
        </div>
    </div>

    <script>
        // Main section switching functionality
        function showMainSection(sectionName) {
            // Hide all main sections
            const mainSections = document.querySelectorAll('.main-section');
            mainSections.forEach(section => {
                section.classList.remove('active');
            });
            
            // Remove active class from all main tabs
            const mainTabs = document.querySelectorAll('.main-tab');
            mainTabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected section
            const targetSection = document.getElementById(sectionName + '-section');
            if (targetSection) {
                targetSection.classList.add('active');
            }
            
            // Add active class to clicked tab
            event.target.classList.add('active');
            
            // Reset sub-tabs when switching main sections
            if (sectionName === 'objectives') {
                // Reset to first tab in objectives section
                const subTabs = document.querySelectorAll('#objectives-section .tab');
                const subSections = document.querySelectorAll('#objectives-section .content-section');
                
                subTabs.forEach(tab => tab.classList.remove('active'));
                subSections.forEach(section => section.classList.remove('active'));
                
                if (subTabs.length > 0) {
                    subTabs[0].classList.add('active');
                }
                if (subSections.length > 0) {
                    subSections[0].classList.add('active');
                }
            }
        }

        // Sub-tab switching functionality
        function switchTab(tabName) {
            // Get the current main section
            const activeMainSection = document.querySelector('.main-section.active');
            if (!activeMainSection) return;
            
            // Hide all content sections in current main section
            const contentSections = activeMainSection.querySelectorAll('.content-section');
            contentSections.forEach(section => {
                section.classList.remove('active');
            });
            
            // Remove active class from all tabs in current main section
            const tabs = activeMainSection.querySelectorAll('.tab');
            tabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected content section
            const targetSection = document.getElementById(tabName);
            if (targetSection) {
                targetSection.classList.add('active');
            }
            
            // Add active class to clicked tab
            event.target.classList.add('active');
        }

        // Initialize the page
        document.addEventListener('DOMContentLoaded', function() {
            // Ensure the first main section and first sub-tab are active on page load
            const firstMainSection = document.querySelector('.main-section');
            const firstMainTab = document.querySelector('.main-tab');
            
            if (firstMainSection && firstMainTab) {
                firstMainSection.classList.add('active');
                firstMainTab.classList.add('active');
            }
            
            // Initialize first sub-tab in objectives section
            const firstSubTab = document.querySelector('#objectives-section .tab');
            const firstSubSection = document.querySelector('#objectives-section .content-section');
            
            if (firstSubTab && firstSubSection) {
                firstSubTab.classList.add('active');
                firstSubSection.classList.add('active');
            }
        });
    </script>
</body>
</html>